Intermittent Fasting & Time-Restricted Eating
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Multiple RCTs and a major NEJM review (de Cabo & Mattson 2019) support metabolic benefits, but isocaloric trials show little effect beyond calorie reduction, and no human trial has measured lifespan or mortality, keeping the specific longevity claim at preliminary/mixed grade.
Reference only. Not medical advice.
Intermittent fasting (IF) and time-restricted eating (TRE) describe eating patterns that cycle between periods of eating and fasting, ranging from daily 6 to 10 hour eating windows (TRE) to full-day fasts on 1 to 2 days per week (5:2) or every other day (alternate-day fasting). The proposed mechanism, sometimes called the metabolic switch, is that after roughly 12 or more hours without food the body shifts from using glucose to using fatty acids and ketones, triggering pathways related to autophagy, reduced oxidative stress, and improved insulin sensitivity. These mechanisms are well documented in rodents, where various fasting regimens have extended lifespan by roughly 10 to 30 percent in some studies. Human evidence is considerably more limited and mixed. Randomized trials, mostly short-term (weeks to about a year) and mostly measuring weight and metabolic markers rather than aging or mortality, show that IF and TRE can produce modest weight loss and improvements in some cardiometabolic markers, roughly comparable to what continuous calorie restriction achieves at a matched calorie deficit. Isocaloric trials, where total calories are matched between groups, generally find no significant additional metabolic benefit from meal timing alone beyond the calorie reduction itself, suggesting that much of the real-world benefit people experience with IF comes from spontaneously eating less, not from fasting-specific biology. No human trial has measured lifespan or all-cause mortality as an outcome, and no clinical guideline body currently endorses intermittent fasting as a therapy for extending lifespan specifically, as opposed to a tool for weight management or glycemic control in select patients. Current status is that IF and TRE are widely self-practiced for weight management and general health, and are being studied clinically for conditions such as type 2 diabetes, shift-worker metabolic health, and cancer treatment adjuncts, but remain experimental for the specific claim of slowing aging or extending lifespan. Caveats include limited long-term data, potential for disordered eating patterns, and populations where fasting is discouraged, including pregnancy, certain medication regimens (particularly insulin and sulfonylureas), a history of eating disorders, and being underweight or frail.
Intermittent fasting (IF) and time-restricted eating (TRE) describe eating patterns that cycle between periods of eating and fasting.
Safety in detail
Fasting protocols are not advised without medical guidance for people who are pregnant, underweight, have a history of eating disorders, or take glucose-lowering medications, due to hypoglycemia and nutritional-adequacy risks.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Periodic fasting has religious and cultural roots going back millennia (for example Ramadan, Yom Kippur, and various Christian and Buddhist fasting traditions), but its modern scientific study grew out of caloric-restriction research in rodents from the mid-20th century onward, when researchers noticed that intermittent feeding schedules could replicate some CR-like effects even without a large reduction in total calories. Human interest accelerated in the 2000s and 2010s with popularized protocols (5:2, alternate-day fasting, 16:8 time-restricted eating) and with mechanistic work from researchers such as Mark Mattson and Valter Longo linking fasting to metabolic switching and stress resistance. A widely cited 2019 New England Journal of Medicine review by de Cabo and Mattson consolidated the mechanistic case and helped popularize the field, while subsequent isocaloric randomized trials in the 2020s have narrowed the claimed benefit, showing that much of the metabolic improvement in free-living settings comes from incidental calorie reduction rather than meal timing itself.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Intermittent Fasting & Time-Restricted Eating. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.